AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More
ASTRAZENECA PHARMA | GSK PHARMA | ASTRAZENECA PHARMA/ GSK PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 114.4 | 54.2 | 210.9% | View Chart |
P/BV | x | 35.0 | 12.2 | 286.2% | View Chart |
Dividend Yield | % | 0.0 | 1.3 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASTRAZENECA PHARMA Mar-18 |
GSK PHARMA Mar-19 |
ASTRAZENECA PHARMA/ GSK PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,278 | 3,595 | 35.5% | |
Low | Rs | 883 | 1,253 | 70.4% | |
Sales per share (Unadj.) | Rs | 228.4 | 184.7 | 123.7% | |
Earnings per share (Unadj.) | Rs | 10.4 | 26.3 | 39.4% | |
Cash flow per share (Unadj.) | Rs | 16.3 | 29.2 | 55.8% | |
Dividends per share (Unadj.) | Rs | 0 | 20.00 | 0.0% | |
Dividend yield (eoy) | % | 0 | 0.8 | 0.0% | |
Book value per share (Unadj.) | Rs | 98.8 | 126.3 | 78.2% | |
Shares outstanding (eoy) | m | 25.00 | 169.40 | 14.8% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 4.7 | 13.1 | 36.0% | |
Avg P/E ratio | x | 104.2 | 92.2 | 113.1% | |
P/CF ratio (eoy) | x | 66.4 | 83.1 | 79.9% | |
Price / Book Value ratio | x | 10.9 | 19.2 | 57.0% | |
Dividend payout | % | 0 | 76.1 | 0.0% | |
Avg Mkt Cap | Rs m | 27,008 | 410,626 | 6.6% | |
No. of employees | `000 | 1.4 | 5.0 | 27.3% | |
Total wages/salary | Rs m | 1,535 | 5,372 | 28.6% | |
Avg. sales/employee | Rs Th | 4,210.9 | 6,306.7 | 66.8% | |
Avg. wages/employee | Rs Th | 1,132.2 | 1,083.1 | 104.5% | |
Avg. net profit/employee | Rs Th | 191.1 | 898.0 | 21.3% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 5,710 | 31,281 | 18.3% | |
Other income | Rs m | 123 | 1,023 | 12.0% | |
Total revenues | Rs m | 5,833 | 32,304 | 18.1% | |
Gross profit | Rs m | 463 | 6,009 | 7.7% | |
Depreciation | Rs m | 147 | 486 | 30.3% | |
Interest | Rs m | 0 | 6 | 0.0% | |
Profit before tax | Rs m | 438 | 6,540 | 6.7% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 287 | 0.0% | |
Tax | Rs m | 179 | 2,373 | 7.5% | |
Profit after tax | Rs m | 259 | 4,454 | 5.8% | |
Gross profit margin | % | 8.1 | 19.2 | 42.2% | |
Effective tax rate | % | 40.8 | 36.3 | 112.6% | |
Net profit margin | % | 4.5 | 14.2 | 31.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 3,209 | 20,061 | 16.0% | |
Current liabilities | Rs m | 2,070 | 14,543 | 14.2% | |
Net working cap to sales | % | 20.0 | 17.6 | 113.1% | |
Current ratio | x | 1.6 | 1.4 | 112.4% | |
Inventory Days | Days | 72 | 57 | 127.4% | |
Debtors Days | Days | 35 | 14 | 248.4% | |
Net fixed assets | Rs m | 790 | 14,343 | 5.5% | |
Share capital | Rs m | 50 | 1,694 | 3.0% | |
"Free" reserves | Rs m | 2,419 | 19,704 | 12.3% | |
Net worth | Rs m | 2,469 | 21,398 | 11.5% | |
Long term debt | Rs m | 0 | 2 | 0.0% | |
Total assets | Rs m | 4,605 | 39,113 | 11.8% | |
Interest coverage | x | NM | 1,091.0 | - | |
Debt to equity ratio | x | 0 | 0 | 0.0% | |
Sales to assets ratio | x | 1.2 | 0.8 | 155.0% | |
Return on assets | % | 5.6 | 11.4 | 49.3% | |
Return on equity | % | 10.5 | 20.8 | 50.4% | |
Return on capital | % | 17.7 | 31.9 | 55.6% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 300 | 534 | 56.1% | |
Fx outflow | Rs m | 2,015 | 7,091 | 28.4% | |
Net fx | Rs m | -1,715 | -6,557 | 26.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 88 | 3,994 | 2.2% | |
From Investments | Rs m | -94 | -1,433 | 6.5% | |
From Financial Activity | Rs m | NA | -3,584 | 0.0% | |
Net Cashflow | Rs m | -6 | -1,023 | 0.6% |
Indian Promoters | % | 0.0 | 0.0 | - | |
Foreign collaborators | % | 75.0 | 50.7 | 147.9% | |
Indian inst/Mut Fund | % | 0.3 | 10.2 | 2.9% | |
FIIs | % | 15.7 | 23.8 | 66.0% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 9.1 | 15.4 | 59.1% | |
Shareholders | 12,856 | 102,036 | 12.6% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASTRAZENECA PHARMA With: CADILA HEALTHCARE TTK HEALTHCARE NEULAND LABS BIOCON J.B.CHEMICALS
Compare ASTRAZENECA PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.
For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
An Indian company founded three decades ago in a garage caught my attention...
In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.
More